Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas
Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this subset of tumors is limited. We sought to asses...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2024-10-01
|
| Series: | Acta Oncologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actaoncologica/article/view/40845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275416136220672 |
|---|---|
| author | Lisa Millgård Sagberg Øyvind Salvesen Asgeir Store Jakola Erik Thurin Eddie de Dios Noah L.A. Nawabi John L. Kilgallon Joshua D. Bernstock Vasileios K. Kavouridis Timothy R. Smith Ole Solheim |
| author_facet | Lisa Millgård Sagberg Øyvind Salvesen Asgeir Store Jakola Erik Thurin Eddie de Dios Noah L.A. Nawabi John L. Kilgallon Joshua D. Bernstock Vasileios K. Kavouridis Timothy R. Smith Ole Solheim |
| author_sort | Lisa Millgård Sagberg |
| collection | DOAJ |
| description | Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this subset of tumors is limited. We sought to assess correlations between PFS and OS, and identify factors associated with PFS, PPS, and OS in patients treated for diffuse supratentorial WHO grade 2 gliomas.
Material and methods: We included 319 patients from three independent observational cohorts. The correlation between PFS and OS was analyzed using independent exponential distributions for PFS and time from progression to death. Cox proportional hazards models were used to determine the effects of covariates on PFS, PPS, and OS.
Results: The overall correlation between PFS and OS was rs0.31. The correlation was rs 0.37 for astrocytomas and rs 0.19 for oligodendrogliomas. Longer PFS did not predict longer PPS. Patients with astrocytomas had shorter PFS, PPS, and OS. Larger preoperative tumor volume was a risk factor for shorter PFS, while older age was a risk factor for shorter PPS and OS. Patients who received early radio- and chemotherapy had longer PFS, but shorter PPS and OS.
Interpretation: We found a weak correlation between PFS and OS in WHO grade 2 gliomas, with the weakest correlation observed in oligodendrogliomas. Our analyses did not demonstrate any association between PFS and PPS. Critically, predictors of PFS are not necessarily predictors of OS. There is a need for validation of PFS as an endpoint in diffuse WHO grade 2 gliomas.
|
| format | Article |
| id | doaj-art-55c989cdf96f4f42b7ad160fa64d224d |
| institution | OA Journals |
| issn | 1651-226X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Oncologica |
| spelling | doaj-art-55c989cdf96f4f42b7ad160fa64d224d2025-08-20T01:50:45ZengMedical Journals SwedenActa Oncologica1651-226X2024-10-0163110.2340/1651-226X.2024.40845Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomasLisa Millgård Sagberg0https://orcid.org/0000-0001-7149-3082Øyvind Salvesen1Asgeir Store Jakola2Erik Thurin3Eddie de Dios4Noah L.A. Nawabi5John L. Kilgallon6Joshua D. Bernstock7Vasileios K. Kavouridis8Timothy R. Smith9Ole Solheim10Department of Neurosurgery, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway Clinical Research Unit, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg, SwedenInstitute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg, Sweden; Department of Radiology, Sahlgrenska University Hospital, Gothenburg, SwedenInstitute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, Gothenburg, Sweden; Department of Radiology, Sahlgrenska University Hospital, Gothenburg, SwedenDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USADepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USADepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USADepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USADepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USADepartment of Neurosurgery, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, NorwayBackground and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this subset of tumors is limited. We sought to assess correlations between PFS and OS, and identify factors associated with PFS, PPS, and OS in patients treated for diffuse supratentorial WHO grade 2 gliomas. Material and methods: We included 319 patients from three independent observational cohorts. The correlation between PFS and OS was analyzed using independent exponential distributions for PFS and time from progression to death. Cox proportional hazards models were used to determine the effects of covariates on PFS, PPS, and OS. Results: The overall correlation between PFS and OS was rs0.31. The correlation was rs 0.37 for astrocytomas and rs 0.19 for oligodendrogliomas. Longer PFS did not predict longer PPS. Patients with astrocytomas had shorter PFS, PPS, and OS. Larger preoperative tumor volume was a risk factor for shorter PFS, while older age was a risk factor for shorter PPS and OS. Patients who received early radio- and chemotherapy had longer PFS, but shorter PPS and OS. Interpretation: We found a weak correlation between PFS and OS in WHO grade 2 gliomas, with the weakest correlation observed in oligodendrogliomas. Our analyses did not demonstrate any association between PFS and PPS. Critically, predictors of PFS are not necessarily predictors of OS. There is a need for validation of PFS as an endpoint in diffuse WHO grade 2 gliomas. https://medicaljournalssweden.se/actaoncologica/article/view/40845Brain NeoplasmsSurrogate endpointsResponse assessment criteriaPrognostic factorsOncology |
| spellingShingle | Lisa Millgård Sagberg Øyvind Salvesen Asgeir Store Jakola Erik Thurin Eddie de Dios Noah L.A. Nawabi John L. Kilgallon Joshua D. Bernstock Vasileios K. Kavouridis Timothy R. Smith Ole Solheim Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas Acta Oncologica Brain Neoplasms Surrogate endpoints Response assessment criteria Prognostic factors Oncology |
| title | Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas |
| title_full | Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas |
| title_fullStr | Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas |
| title_full_unstemmed | Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas |
| title_short | Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas |
| title_sort | progression free survival versus post progression survival and overall survival in who grade 2 gliomas |
| topic | Brain Neoplasms Surrogate endpoints Response assessment criteria Prognostic factors Oncology |
| url | https://medicaljournalssweden.se/actaoncologica/article/view/40845 |
| work_keys_str_mv | AT lisamillgardsagberg progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT øyvindsalvesen progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT asgeirstorejakola progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT erikthurin progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT eddiededios progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT noahlanawabi progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT johnlkilgallon progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT joshuadbernstock progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT vasileioskkavouridis progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT timothyrsmith progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas AT olesolheim progressionfreesurvivalversuspostprogressionsurvivalandoverallsurvivalinwhograde2gliomas |